Compared with other biologics frequently used in China for moderate-to-severe psoriasis, secukinumab is the most cost-effective treatment option.
Secukinumab is the most cost-effective treatment option for patients with moderate-to-severe psoriasis compared with other biologics frequently used from the perspective of the Chinese health care system, according to a study from Dermatology and Therapy.
Currently, there are no approved secukinumab (Cosentyx) biosimilars, although some are in development. Bio-Thera Solutions is conducting Phase 3 trials for the clinical development of a secukinumab biosimilar for plaque psoriasis as of September 11, 2023, according to Pharmaceutical Technology.2 The Phase 3 trial was initiated in November 2022, and at the time Bio-Thera Solutions stated that it will file for regulatory approval for all indications of the reference product in the European Union, United Kingdom, China, and United States upon completion of the trial. The patent on the reference product will expire between from 2025 to 2026.3
Patients with moderate-to-severe psoriasis usually need treatment throughout their life, and psoriasis presents a large economic burden on patients and their families in China. The total yearly expenditure because of psoriasis accounts for approximately 20.0% of patients’ income and cumulates into a yearly hospitalization rate of 21.3%, 15.0 days of sick leave, and a 37.0% rate of unemployment.
First, the study evaluated the cost effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and etanercept biosimilar [Yisaipu]) for the treatment of moderate-to-severe plaque psoriasis from the perspective of the Chinese health care system.
A decision-tree (first year)/Markov model (subsequent years), with a yearly cycle, was implemented over a lifetime. The Psoriasis Area and Severity Index (PASI) response rate at week 16 was utilized for treatment response. Efficacy inputs were collected from a mixed-treatment comparison conducted using randomized controlled trial data.
Other clinical inputs (like adverse events, dropout, and mortality rates), utility weights, and costs were originated from published literature and local Chinese sources. Costs and outcomes were discounted at 5% per annum. Model outcomes contained quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were administered to test result robustness.
It was found that secukinumab produced the highest QALYs (12.334) against all comparators at a lifetime cost of ¥231,477 (approximately $31,661) for patients with moderate-to-severe psoriasis. Secukinumab overpowered (higher QALYs at lower costs) all other biologics except ixekizumab in this population. Ixekizumab acquired slightly lower costs (¥228,320 [$31,229]) but obtained lesser QALYs (12.284), compared with secukinumab. So, secukinumab was a cost-effective treatment than ixekizumab at a willingness-to-pay (WTP) threshold of ¥257,094 ($35,164) per QALY acquired.
“In the one-way sensitivity analysis, base-case results were most sensitive to changes in the PASI response at 16 weeks and year 2+ dropout rates,” continued the researchers.
Additionally, the researchers found that secukinumab was a cost-effective treatment option versus adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and etanercept biosimilar (Yisapu) among patients with moderate-to-severe psoriasis over a lifetime.
“The results of base-case analysis were most sensitive to changes in the PASI response at 16 weeks and year 2+ dropout rates for all treatment comparisons,” said the researchers.
Results similar to base-case analysis validating the cost-effectiveness of secukinumab were also seen in the alternative scenario analysis.
To the researchers’ knowledge, this is the first comprehensive economic evaluation comparing the costs and benefits (QALYs) linked with secukinumab compared to other commonly used biologics in the Chinese health care setting.
Some limitations were present in this study. The model used short-term efficacy data to project lifetime efficacy, stemming from the network meta-analysis that was limited to week 16 because of crossover of treatment arms past week 12 or week 16. Also, treatment sequencing was present, because the current analysis was restricted to first-line biologic treatment only.
“This cost-effectiveness analysis demonstrated that secukinumab is the most cost-effective treatment option compared with other commonly used biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu) for moderate-to-severe plaque psoriasis in China over a lifetime horizon,” concluded the researchers.
Reference
1. Zhang J, Xia Z, Guo W. et al. Cost-effectiveness of secukinumab versus other biologics in the treatment of moderate-to-severe plaque psoriasis: the Chinese healthcare system perspective. Dermatol Ther (Heidelb) Published online September 23, 2023. doi:10.1007/s13555-023-01041-8
2. Secukinumab biosimilar by bio-thera Solutions for plaque psoriasis (psoriasis vulgaris): likelihood of approval. pharmaceutical technology. Published September 11, 2023. Accessed September 27, 2023. https://www.pharmaceutical-technology.com/data-insights/secukinumab-biosimilar-bio-thera-solutions-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/#:~:text=Secukinumab%20biosimilar%20overview,is%20administered%20through%20subcutaneous%20route
3. Higgins-Dunn N. The top 15 blockbuster patent expirations coming this decade. Fierce Pharma. Published July 12, 2021. Accessed September 27, 2023. https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.